Latest Unigene Laboratories Stories
PHILADELPHIA, March 24, 2011 /PRNewswire/ -- Tarsa Therapeutics today announced that the Phase III ORACAL trial of its oral recombinant salmon calcitonin in the treatment of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, positive top-line results.
BOONTON, N.J., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Unigene Laboratories, Inc.
PHILADELPHIA, BOONTON, N.J. and BRUSSELS, Sept. 24 /PRNewswire/ -- Tarsa Therapeutics, Inc. and Unigene Laboratories, Inc.
BOONTON, N.J., August 6 /PRNewswire/ -- Unigene Laboratories, Inc.
Patients who start and eventually stop regimens of a common class of osteoporosis drugs called bisphosphonates may be unable to benefit from parathyroid hormone (PTH), which can rebuild bone mass lost due to advanced stage osteoporosis.